Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BelCaP versus carboplatin + paclitaxel in previously untreated carcinoma of unknown primary
2008-005865-67Phase 2Completed
- Sponsor
- TopoTarget
- Start
- Nov 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of belinostat, carboplatin and paclitaxel in cancer of unknown primary (CUP) (2 arms), sponsored by TopoTarget. Primary endpoint: Progression-free survival. Started Nov 2008; status: completed.
02
Drugs
belinostatcarboplatinpaclitaxel
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on 2008-005865-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005865-67.